studies

mBC - TNBC - L1 - all population, pembrolizumab based treatment vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsKEYNOTE-355 (all population), 2020 0.89 [0.76; 1.05] 0.89[0.76; 1.05]KEYNOTE-355 (all population), 202010%847NAnot evaluable progression or deaths (PFS)detailed resultsKEYNOTE-355 (all population), 2020 0.82 [0.69; 0.97] 0.82[0.69; 0.97]KEYNOTE-355 (all population), 202010%847NAnot evaluable objective responses (ORR)detailed resultsKEYNOTE-355 (all population), 2020 0.24 [0.17; 0.33] 0.24[0.17; 0.33]KEYNOTE-355 (all population), 202010%847NAnot evaluable AE (any grade)detailed resultsKEYNOTE-355 (all population), 2020 1.25 [0.41; 3.87] 1.25[0.41; 3.87]KEYNOTE-355 (all population), 202010%843NAnot evaluable AE (grade 3-4)detailed resultsKEYNOTE-355 (all population), 2020 1.26 [0.91; 1.76] 1.26[0.91; 1.76]KEYNOTE-355 (all population), 202010%843NAnot evaluable TRAE (any grade)detailed resultsKEYNOTE-355 (all population), 2020 1.35 [0.68; 2.70] 1.35[0.68; 2.70]KEYNOTE-355 (all population), 202010%843NAnot evaluable TRAE (grade 3-4)detailed resultsKEYNOTE-355 (all population), 2020 1.06 [0.78; 1.44] 1.06[0.78; 1.44]KEYNOTE-355 (all population), 202010%843NAnot evaluable TRAE leading to death (grade 5)detailed resultsKEYNOTE-355 (all population), 2020 2.00 [0.09; 44.58] 2.00[0.09; 44.58]KEYNOTE-355 (all population), 202010%843NAnot evaluable Alopecia TRAE (grade 3-4)detailed resultsKEYNOTE-355 (all population), 2020 0.83 [0.20; 3.51] 0.83[0.20; 3.51]KEYNOTE-355 (all population), 202010%843NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsKEYNOTE-355 (all population), 2020 1.15 [0.77; 1.71] 1.15[0.77; 1.71]KEYNOTE-355 (all population), 202010%843NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsKEYNOTE-355 (all population), 2020 2.00 [0.09; 44.58] 2.00[0.09; 44.58]KEYNOTE-355 (all population), 202010%843NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsKEYNOTE-355 (all population), 2020 1.15 [0.47; 2.82] 1.15[0.47; 2.82]KEYNOTE-355 (all population), 202010%843NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-355 (all population), 2020 1.00 [0.03; 29.90] 1.00[0.03; 29.90]KEYNOTE-355 (all population), 202010%843NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-355 (all population), 2020 2.00 [0.09; 44.58] 2.00[0.09; 44.58]KEYNOTE-355 (all population), 202010%843NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsKEYNOTE-355 (all population), 2020 1.29 [0.67; 2.48] 1.29[0.67; 2.48]KEYNOTE-355 (all population), 202010%843NAnot evaluable Leucopenia TRAE (grade 3-4)detailed resultsKEYNOTE-355 (all population), 2020 0.83 [0.58; 1.19] 0.83[0.58; 1.19]KEYNOTE-355 (all population), 202010%843NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsKEYNOTE-355 (all population), 2020 1.13 [0.34; 3.69] 1.13[0.34; 3.69]KEYNOTE-355 (all population), 202010%843NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-355 (all population), 2020 0.99 [0.73; 1.36] 0.99[0.73; 1.36]KEYNOTE-355 (all population), 202010%843NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsKEYNOTE-355 (all population), 2020 6.05 [0.34; 108.78] 6.05[0.34; 108.78]KEYNOTE-355 (all population), 202010%843NAnot evaluable Severe skin reaction TRAE (grade 3-4)detailed resultsKEYNOTE-355 (all population), 2020 10.16 [0.59; 174.64] 10.16[0.59; 174.64]KEYNOTE-355 (all population), 202010%843NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:19 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 60 - treatments: 847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561